Pegscholar Bio: The new generation GLP-1 can maintain metabolic intervention effects in healthy cynomolgus monkey model for several weeks after a single subcutaneous injection.

PegBio announcement: The company has independently developed a new generation GLP-1 receptor agonist CR059 based on circular RNA protein replacement technology and combined with artificial intelligence-assisted molecular design platform. This candidate product, which is part of the PB-2309 triple receptor agonist project's phased development strategy, targets the GLP-1 receptor agonist mechanism for preliminary clinical validation. Single-dose administration has been completed in subjects and one month of human clinical observation results have been obtained.